207 results on '"Duvall, Adam"'
Search Results
2. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma
3. Tailoring Solution-Focused Brief Therapy for Adolescents and Young Adults with Cancer: A Qualitative Investigation
4. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults
5. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis
6. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
7. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
8. Effectiveness of cognitive behavioral therapy in improving functional health in cancer survivors: A systematic review and meta-analysis
9. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study.
10. Pulmonary Complications
11. Achievement of therapeutic levels using dose-reduced peg-asparaginase in adult patients with acute lymphoblastic leukemia.
12. A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients.
13. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation
14. Development of a Patient-Reported Sexual Health Outcomes Battery for Use in Adolescent and Young Adult Cancer Clinical Trials
15. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
16. Case Presentation: Adoption in the Cancer Setting
17. Adoption in the Cancer Setting
18. Case Presentation: Sperm Banking in Patient Diagnosed with Acute Myeloid Leukemia
19. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia
20. Treating Mental Health and Quality of Life in Older Cancer Patients with Cognitive Behavioral Therapy: A Systematic Review and Meta-Analysis.
21. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors
22. Durable Responses in Acute Lymphoblastic Leukemia Using Targeted Therapies Approved for Acute Myeloid Leukemia
23. Disparities in care and outcomes for adolescent and young adult lymphoma patients
24. Data from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
25. Supplementary figures 1-9 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
26. Supplementary Table 1 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
27. P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)
28. P354: MULTI-INSTITUTIONAL STUDY EVALUATING THE IMPACT ON SURVIVAL OF NEWER TREATMENT COMBINATIONS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
29. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
30. Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure
31. Gaps in Adolescent and Young Adult Cancer Education in Oncology Fellowship Training
32. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
33. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis
34. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors
35. Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
36. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia
37. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
38. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
39. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
40. Clinical and molecular response of AML harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors
41. Validation and clinical application of transactivation assays for RUNX1 variant classification
42. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
43. Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies.
44. When and how to deliver oncology supportive care resources: An adolescent and young adult perspective.
45. Gaps in adolescent and young adult oncology education during medical and pediatric hematology/oncology fellowship training.
46. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
47. Racial disparities in patients with TP53 mutated acute myeloid leukemia.
48. Validation and clinical application of transactivation assays forRUNX1variant classification
49. Outcomes ofTP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
50. Evaluating the Feasibility and Acceptability of an Artificial-Intelligence-Enabled and Speech-Based Distress Screening Mobile App for Adolescents and Young Adults Diagnosed with Cancer: A Study Protocol
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.